Professor Henning Walczak

Publications


Journals

  • Micheau O; Dufour F; Walczak H. (29 Nov 2011). Glory Lily's semi-synthetic derivative Thiocolchicoside: a new weapon to fight metastatic bone resorption?. Br J Pharmacol. DOI.
  • Rizza SA; Challagundla KB; Natesampillai S; Bren GD; Sykora J; Walczak H; Badley AD. (2011). TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One. 6:e27171. DOI.
  • Walczak H. (Nov 2011). TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev. 244:9-28. DOI.
  • Vaughan S; Coward JI; Bast RC; Berchuck A; Berek JS; Brenton JD; Coukos G; Crum CC; et alDrapkin R; Etemadmoghadam D; Friedlander M; Gabra H; Kaye SB; Lord CJ; Lengyel E; Levine DA; McNeish IA; Menon U; Mills GB; Nephew KP; Oza AM; Sood AK; Stronach EA; Walczak H; Bowtell DD; Balkwill FR. (Oct 2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 11:719-725. DOI.
  • Resch U; Semlitsch M; Hammer A; Susani-Etzerodt H; Walczak H; Sattler W; Malle E. (15 Jul 2011). Hypochlorite-modified low-density lipoprotein induces the apoptotic machinery in Jurkat T-cell lines. Biochem Biophys Res Commun. 410:895-900. DOI.
  • Gerlach B; Cordier SM; Schmukle AC; Emmerich CH; Rieser E; Haas TL; Webb AI; Rickard JA; et alAnderton H; Wong WW; Nachbur U; Gangoda L; Warnken U; Purcell AW; Silke J; Walczak H. (31 Mar 2011). Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 471:591-596. DOI.
  • Kantari C; Walczak H. (Apr 2011). Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta. 1813:558-563. DOI.
  • Emmerich CH; Schmukle AC; Haas TL; Gerlach B; Cordier SM; Rieser E; Walczak H. (2011). The linear ubiquitin chain assembly complex forms part of the TNF-R1 signalling complex and is required for effective TNF-induced gene induction and prevents TNF-induced apoptosis. Adv Exp Med Biol. 691:115-126. DOI.
  • Aydin D; Louban I; Perschmann N; Blümmel J; Lohmüller T; Cavalcanti-Adam EA; Haas TL; Walczak H; et alKessler H; Fiammengo R; Spatz JP. (5 Oct 2010). Polymeric substrates with tunable elasticity and nanoscopically controlled biomolecule presentation. Langmuir. 26:15472-15480. DOI.
  • Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; et alKashkar H; Walczak H; Delia D. (8 Jun 2010). Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer. 102:1707-1716. DOI.
  • Barisic S; Schmidt C; Walczak H; Kulms D. (15 Aug 2010). Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFkappaB activation via Src-dependent blockade of PP2A. Biochem Pharmacol. 80:439-447. DOI.
  • Hoogwater FJ; Nijkamp MW; Smakman N; Steller EJ; Emmink BL; Westendorp BF; Raats DA; Sprick MR; et alSchaefer U; Van Houdt WJ; De Bruijn MT; Schackmann RC; Derksen PW; Medema JP; Walczak H; Borel Rinkes IH; Kranenburg O. (Jun 2010). Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology. 138:2357-2367. DOI.
  • Vince JE; Pantaki D; Feltham R; Mace PD; Cordier SM; Schmukle AC; Davidson AJ; Callus BA; et alWong WW; Gentle IE; Carter H; Lee EF; Walczak H; Day CL; Vaux DL; Silke J. (18 Dec 2009). TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem. 284:35906-35915. DOI.
  • Haas TL; Emmerich CH; Gerlach B; Schmukle AC; Cordier SM; Rieser E; Feltham R; Vince J; et alWarnken U; Wenger T; Koschny R; Komander D; Silke J; Walczak H. (11 Dec 2009). Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 36:831-844. DOI.
  • Brost S; Koschny R; Sykora J; Stremmel W; Lasitschka F; Walczak H; Ganten TM. (15 Jan 2010). Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathol Res Pract. 206:43-50. DOI.
  • Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; et alWalczak H. (Oct 2009). Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J MOL MED-JMM. 87:995-1007. DOI.
  • Koschny R; Holland H; Sykora J; Erdal H; Krupp W; Bauer M; Bockmuehl U; Ahnert P; et alMeixensberger J; Stremmel W; Walczak H; Ganten TM. (Apr 2010). Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J Neurooncol. 97:171-185. DOI.
  • Strauss G; Lindquist JA; Arhel N; Felder E; Karl S; Haas TL; Fulda S; Walczak H; et alKirchhoff F; Debatin KM. (8 Jun 2009). CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. J Exp Med. 206:1379-1393. DOI.
  • Falschlehner C; Schaefer U; Walczak H. (Jun 2009). Following TRAIL's path in the immune system. Immunology. 127:145-154. DOI.
  • Aydin D; Schwieder M; Louban I; Knoppe S; Ulmer J; Haas TL; Walczak H; Spatz JP. (May 2009). Micro-nanostructured protein arrays: a tool for geometrically controlled ligand presentation. Small. 5:1014-1018. DOI.
  • Aydin D; Schwieder M; Louban I; Knoppe S; Ulmer J; Haas TL; Walczak H; Spatz JP. (22 Apr 2009). Gold nanoparticles: Small 9/2009. Small. 5. DOI.
  • Newsom-Davis T; Prieske S; Walczak H. (Apr 2009). Is TRAIL the holy grail of cancer therapy?. Apoptosis. 14:607-623. DOI.
  • Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; et alMoller P; Gschwend JE; Simmet T; Debatin KM; Fulda S. (15 Mar 2009). Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. CANCER RES. 69:2425-2434. DOI.
  • Macher-Goeppinger S; Aulmann S; Tagscherer KE; Wagener N; Haferkamp A; Penzel R; Brauckhoff A; Hohenfellner M; et alSykora J; Walczak H; Teh BT; Autschbach F; Herpel E; Schirmacher P; Roth W. (15 Jan 2009). Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. CLIN CANCER RES. 15:650-659. DOI.
  • Cordier SM; Papenfuss K; Walczak H. (2009). From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy. Results Probl Cell Differ. 49:115-143. DOI.
  • Falschlehner C; Ganten TM; Koschny R; Schaefer U; Walczak H. (2009). TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics. ADV EXP MED BIOL. 647:195-206.
  • Grund K; Ahmadi R; Jung F; Funke V; Gdynia G; Benner A; Sykora J; Walczak H; et alJoos S; Felsberg J; Reifenberger G; Wiestler OD; Herold-Mende C; Roth W. (Dec 2008). Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol Ther. 7:1982-1990.
  • Papenfuss K; Cordier SM; Walczak H. (Dec 2008). Death receptors as targets for anti-cancer therapy. J CELL MOL MED. 12:2566-2585. DOI.
  • Barisic S; Strozyk E; Peters N; Walczak H; Kulms D. (Nov 2008). Identification of PP2A as a crucial regulator of the NF-kappa B feedback loop: its inhibition by UVB turns NF-kappa B into a pro-apoptotic factor. CELL DEATH DIFFER. 15:1681-1690. DOI.
  • Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; et alDebatin KM; Fulda S. (1 Oct 2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. CANCER RES. 68:7956-7965. DOI.
  • Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; et alGollnick H; Walczak H; Leverkus M. (15 May 2008). Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene. 27:3211-3220. DOI.
  • Diessenbacher P; Hupe M; Sprick MR; Kerstan A; Geserick P; Haas TL; Wachter T; Neumann M; et alWalczak H; Silke J; Leverkus M. (May 2008). NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J Invest Dermatol. 128:1134-1147. DOI.
  • Todaro M; Lombardo Y; Francipane MG; Alea MP; Cammareri P; Iovino F; Di Stefano AB; Di Bernardo C; et alAgrusa A; Condorelli G; Walczak H; Stassi G. (Apr 2008). Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. CELL DEATH DIFFER. 15:762-772. DOI.
  • Eckert A; Böck BC; Tagscherer KE; Haas TL; Grund K; Sykora J; Herold-Mende C; Ehemann V; et alHollstein M; Chneiweiss H; Wiestler OD; Walczak H; Roth W. (14 Feb 2008). The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway. Oncogene. 27:1155-1166. DOI.
  • Verbrugge I; de Vries E; Tait SWG; Wissink EHJ; Walczak H; Verheij M; Borst J. (24 Jan 2008). Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. ONCOGENE. 27:574-584. DOI.
  • Grosse-Wilde A; Voloshanenko O; Bailey SL; Longton GM; Schaefer U; Csernok AI; Schütz G; Greiner EF; et alKemp CJ; Walczak H. (Jan 2008). TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest. 118:100-110. DOI.
  • Walczak H; Haas TL. (2008). Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol Biol. 414:221-239.
  • Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; et alAhnert P; Meixensberger J; Walczak H. (1 Dec 2007). Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 (November, pg 6541, 2007). CLIN CANCER RES. 13:7224-7224. DOI.
  • Koschny R; Sykora J; Walczak H; Ganten TM; Haas TL; Sprick MR; Holland H; Ahnert P; et alKrupp W; Meixensberger J; Bauer M. (1 Nov 2007). Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 is not necessary for but contributes to sensitization of primary human glioma cells to TRAIL. CLIN CANCER RES. 13:6541-6542. DOI.
  • Koschny R; Walczak H; Ganten TM. (Sep 2007). The promise of TRAIL - potential and risks of a novel anticancer therapy. J MOL MED-JMM. 85:923-935. DOI.
  • Gassler N; Roth W; Funke B; Schneider A; Herzog F; Tischendorf JJW; Grund K; Penzel R; et alBravo IG; Mariadason J; Ehemann V; Sykora J; Haas TL; Walczak H; Ganten T; Zentgraf H; Erb P; Alonso A; Autschbach F; Schirmacher P; Knuchel R; Kopitz J. (Aug 2007). Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. GASTROENTEROLOGY. 133:587-598. DOI.
  • Werdehausen R; Braun S; Essmann F; Schulze-Osthoff K; Walczak H; Lipfert P; Stevens MF. (Jul 2007). Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. ANESTHESIOLOGY. 107:136-143.
  • Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; et alAhnert P; Meixensberger J; Walczak H. (1 Jun 2007). Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 13:3403-3412. DOI.
  • Wenger T; Mattern J; Haas TL; Sprick MR; Walczak H; Debatin KM; Büchler MW; Herr I. (Mar 2007). Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. 14:316-326. DOI.
  • Koschny R; Ganten TM; Sykora J; Haas TL; Sprick MR; Kolb A; Stremmel W; Walczak H. (Mar 2007). TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology. 45:649-658. DOI.
  • Ritsou E; Breitkreutz R; Benner A; Böhler T; Weigand MA; Walczak H; Gougeon ML; Krammer PH. (Mar 2007). CD4/CXCR4-mediated cell death in AIDS. Cell Death Differ. 14:634-636. DOI.
  • Ganten TM; Aravena E; Sykora J; Koschny R; Mohr J; Rudi J; Stremmel W; Walczak H. (Feb 2007). Helicobacter pylori-induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors. EUR J CLIN INVEST. 37:117-125.
  • Hernandez P; Rodriguez PC; Delgado R; Walczak H. (Feb 2007). Protective effect of Mangifera indica L. polyphenols on human T lymphocytes against activation-induced cell death. Pharmacol Res. 55:167-173. DOI.
  • Roth W; Eckert A; Bock B; Sykora J; Herold-Mende C; Walczak H; Schirmacher P; Wiestler OD. (2007). The PEA-15 protein induces resistance against glucose deprivation-induced cell death via the ERK/MAP kinase pathway. PATHOL RES PRACT. 203:393-394.
  • Schaefer U; Voloshanenko O; Willen D; Walczak H. (2007). TRAIL: a multifunctional cytokine. Front Biosci. 12:3813-3824.
  • Falschlehner C; Emmerich CH; Gerlach B; Walczak H. (2007). TRAIL signalling: Decisions between life and death. INT J BIOCHEM CELL B. 39:1462-1475. DOI.
  • Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; et alDebatin KM; Herr I. (Oct 2006). Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ. 13:1740-1751. DOI.
  • Hernández P; Delgado R; Walczak H. (Sep 2006). Mangifera indica L. extract protects T cells from activation-induced cell death. Int Immunopharmacol. 6:1496-1505. DOI.
  • Wissink EH; Verbrugge I; Vink SR; Schader MB; Schaefer U; Walczak H; Borst J; Verheij M. (Aug 2006). TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol. 80:214-222. DOI.
  • Walczak H. (15 Jul 2006). Per aspera ad astra: from early T-cell development to accelerating late T-cell apoptosis. BLOOD. 108:410-410.
  • Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trauhwein C; et alMichalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Muller M. (15 Jul 2006). Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. CANCER RES. 66:7059-7066. DOI.
  • Walczak H. (1 May 2006). Polycythemia vera erythroblasts: too tough to die. BLOOD. 107:3422-3423.
  • Ganten TM; Koschny R; Sykora J; Schulze-Bergkamen H; Büchler P; Haas TL; Schader MB; Untergasser A; et alStremmel W; Walczak H. (15 Apr 2006). Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 12:2640-2646. DOI.
  • Patre M; Tabbert A; Hermann D; Walczak H; Rackwitz HR; Cordes VC; Ferrando-May E. (13 Jan 2006). Caspases target only two architectural components within the core structure of the nuclear pore complex. J Biol Chem. 281:1296-1304. DOI.
  • Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H. (Sep 2005). Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology. 42:588-597. DOI.
  • Herzer K; Ganten TM; Schulze-Bergkamen H; Grosse-Wilde A; Koschny R; Krammer PH; Walczak H. (Jul 2005). Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology. 42:183-192. DOI.
  • Wachter T; Sprick M; Hausmann D; Kerstan A; McPherson K; Stassi G; Bröcker EB; Walczak H; et alLeverkus M. (17 Dec 2004). cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem. 279:52824-52834. DOI.
  • Wurzer WJ; Ehrhardt C; Pleschka S; Berberich-Siebelt F; Wolff T; Walczak H; Planz O; Ludwig S. (23 Jul 2004). NF-kappa B-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J BIOL CHEM. 279:30931-30937. DOI.
  • Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; et alGrosse-Wilde A; Stremmel W; Krammer PH; Walczak H. (Jul 2004). Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 11 Suppl 1:S86-S96. DOI.
  • Shinbori T; Walczak H; Krammer PH. (Jun 2004). Activated T killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF-alpha. Eur J Immunol. 34:1762-1770. DOI.
  • Demjen D; Klussmann S; Kleber S; Zuliani C; Stieltjes B; Metzger C; Hirt UA; Walczak H; et alFalk W; Essig M; Edler L; Krammer PH; Martin-Villalba A. (Apr 2004). Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. NAT MED. 10:389-395. DOI.
  • Bremer E; Kuulen J; Samplonius D; Walczak H; De Leu L; Helfrich W. (20 Mar 2004). Target cell-restricted and -enhanced apoptosis induction by a scFv : sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. INT J CANCER. 109:281-290. DOI.
  • Sprick MR; Walczak H. (1 Mar 2004). The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta. 1644:125-132. DOI.
  • Leverkus M; Sprick MR; Wachter T; Denk A; Brocker EB; Walczak H; Neumann M. (Jul 2003). TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: Differential contribution of TRAIL receptors 1 and 2. J INVEST DERMATOL. 121:149-155.
  • Hasel C; Durr S; Rau B; Strater J; Schmid RM; Walczak H; Bachem MG; Moller P. (Jun 2003). In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas. LAB INVEST. 83:825-836. DOI.
  • Tiede I; Fritz G; Strand S; Poppe D; Dvorsky R; Strand D; Lehr HA; Wirtz S; et alBecker C; Atreya R; Mudter J; Hildner K; Bartsch B; Holtmann M; Blumberg R; Walczak H; Iven H; Galle PR; Ahmadian MR; Neurath MF. (Apr 2003). CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 111:1133-1145. DOI.
  • Washburn B; Weigand MA; Grosse-Wilde A; Janke M; Stahl H; Rieser E; Sprick MR; Schirrmacher V; et alWalczak H. (15 Feb 2003). TNF-Related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J IMMUNOL. 170:1814-1821.
  • Leverkus M; Sprick MR; Wachter T; Mengling T; Baumann B; Serfling E; Brocker EB; Goebeler M; et alNeumann M; Walczak H. (Feb 2003). Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. MOL CELL BIOL. 23:777-790. DOI.
  • Eggert A; Sieverts H; Walczak H. (2003). Apoptosis induction by TRAIL. Methods Mol Biol. 215:95-116.
  • Schmaltz C; Alpdogan O; Kappel BJ; Muriglan SJ; Rotolo JA; Ongchin J; Willis LM; Greenberg AS; et alEng JM; Crawford JM; Murphy GF; Yagita H; Walczak H; Peschon JJ; van den Brink MRM. (Dec 2002). T cells require TRAIL for optimal graft-versus-tumor activity. NAT MED. 8:1433-1437. DOI.
  • Sträter J; Hinz U; Walczak H; Mechtersheimer G; Koretz K; Herfarth C; Möller P; Lehnert T. (Dec 2002). Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res. 8:3734-3740.
  • Sprick MR; Rieser E; Stahl H; Grosse-Wilde A; Weigand MA; Walczak H. (2 Sep 2002). Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21:4520-4530.
  • Leverkus M; Sprick MR; Mengling T; Baumann B; Serfling E; Brocker EB; Goebeler M; Neumann M; et alWalczak H. (Sep 2002). Proteasome inhibition results in trail sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. J INVEST DERMATOL. 119:743-743.
  • Mueller S; Weber A; Fritz R; Mutze S; Rost D; Walczak H; Volkl A; Stremmel W. (1 May 2002). Sensitive and real-time determination of H2O2 release from intact peroxisomes. BIOCHEM J. 363:483-491.
  • Cotter T; De Laurenzi V; Walczak H; Melino G; Schulze-Osthoff K. (May 2002). The European death flying circus. Cell Death Differ. 9:591-592. DOI.
  • Beltinger C; Fulda S; Walczak H; Debatin KM. (Apr 2002). TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. CANCER GENE THER. 9:372-381. DOI.
  • Tiede I; Wirtz S; Strand S; Strand D; Atreya R; Mudter J; Hildner K; Holtmann M; et alBartsch B; Lehr HA; Blumberg RS; Walczak H; Galle PR; Neurath M. (Apr 2002). CD28-induced Rac-GTP activity is the molecular target of azathioprine in primary human CD4+ T lymphocytes: A mechanism for azathioprine-mediated immunosuppression in IBD based on the induction of T cell apoptosis. GASTROENTEROLOGY. 122:A14-A14.
  • Muerkoster S; Weigand MA; Choi C; Walczak H; Schirrmacher V; Umansky V. (4 Mar 2002). Superantigen reactive V beta 6(+) T cells induce perforin/granzyme B mediated caspase-independent apoptosis in tumour cells. BRIT J CANCER. 86:828-836. DOI.
  • Strater J; Walczak H; Pukrop T; Von Muller L; Hasel C; Kornmann M; Mertens T; Moller P. (Mar 2002). TRAIL and its receptors in the colonic epithelium: A putative role in the defense of viral infections. GASTROENTEROLOGY. 122:659-666. DOI.
  • Dörr J; Bechmann I; Waiczies S; Aktas O; Walczak H; Krammer PH; Nitsch R; Zipp F. (15 Feb 2002). Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci. 22:RC209.
  • Raftery MJ; Schwab M; Eibert SM; Samstag Y; Walczak H; Schönrich G. (Dec 2001). Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity. 15:997-1009.
  • Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M. (12 Jul 2001). CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene. 20:4128-4137. DOI.
  • Trauzold A; Wermann H; Arlt A; Schütze S; Schäfer H; Oestern S; Röder C; Ungefroren H; et alLampe E; Heinrich M; Walczak H; Kalthoff H. (12 Jul 2001). CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene. 20:4258-4269. DOI.
  • Walczak H; Sprick MR. (Jul 2001). Biochemistry and function of the DISC. TRENDS BIOCHEM SCI. 26:452-453.
  • Simon AK; Williams O; Mongkolsapaya J; Jin B; Xu XN; Walczak H; Screaton GR. (24 Apr 2001). Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes. P NATL ACAD SCI USA. 98:5158-5163.
  • Strater J; Walczak H; Hasel C; Melzner I; Leithauser F; Moller P. (Mar 2001). CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. CELL DEATH DIFFER. 8:273-278.
  • Hinz S; Trauzold A; Boenicke L; Sandberg C; Beckmann S; Bayer E; Walczak H; Kalthoff H; et alUngefroren H. (16 Nov 2000). Bcl-X-L protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. ONCOGENE. 19:5477-5486.
  • Funk JO; Walczak H; Voigtlander C; Berchtold S; Baumeister T; Rauch P; Rossner S; Steinkasserer A; et alSchuler G; Lutz MB. (1 Nov 2000). Cutting edge: Resistance to apoptosis and continuous proliferation of dendritic cells deficient for TNF receptor-1. J IMMUNOL. 165:4792-4796.
  • Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD. (Nov 2000). Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 7:1127-1136. DOI.
  • Leverkus M; Walczak H; McLellan A; Fries HW; Terbeck G; Brocker EB; Kampgen E. (1 Oct 2000). Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. BLOOD. 96:2628-2631.
  • Wendling U; Walczak H; Dorr J; Jaboci C; Weller M; Krammer PH; Zipp F. (Jul 2000). Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. CELL DEATH DIFFER. 7:637-644.
  • Walczak H; Bouchon A; Stahl H; Krammer PH. (1 Jun 2000). Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2-or Bcl-x(L)-overexpressing chemotherapy-resistant tumor cells. CANCER RES. 60:3051-3057.
  • Sprick MR; Weigand MA; Rieser E; Rauch CT; Juo P; Blenis J; Krammer PH; Walczak H. (Jun 2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 12:599-609.
  • Walczak H; Krammer PH. (10 Apr 2000). The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. EXP CELL RES. 256:58-66.
  • Keogh SA; Walczak H; Bouchier-Hayes L; Martin SJ. (7 Apr 2000). Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett. 471:93-98.
  • Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H. (1 Feb 2000). Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 60:553-559.
  • Los M; Walczak H; Schulze-Osthoff K; Reed JC. (2000). Fluorogenic substrates as detectors of caspase activity during natural killer cell-induced apoptosis. Methods Mol Biol. 121:155-162. DOI.
  • Bouchon A; Krammer PH; Walczak H. (Jan 2000). Critical role for mitochondria in B cell receptor-mediated apoptosis. Eur J Immunol. 30:69-77. DOI.
  • Raftery MJ; Behrens CK; Müller A; Krammer PH; Walczak H; Schönrich G. (18 Oct 1999). Herpes simplex virus type 1 infection of activated cytotoxic T cells: Induction of fratricide as a mechanism of viral immune evasion. J Exp Med. 190:1103-1114.
  • Schmitz I; Walczak H; Krammer PH; Peter ME. (Sep 1999). Differences between CD95 type I and type II cells detected with the CD95 ligand. CELL DEATH DIFFER. 6:821-822.
  • Walczak H; Miller RE; Ariail K; Gliniak B; Griffith TS; Kubin M; Chin W; Jones J; et alWoodward A; Le T; Smith C; Smolak P; Goodwin RG; Rauch CT; Schuh JCL; Lynch DH. (Feb 1999). Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. NAT MED. 5:157-163.
  • Strater J; Mariani SM; Walczak H; Rucker FG; Leithauser F; Krammer PH; Moller P. (Jan 1999). CD95 ligand (CD95L) in normal human lymphoid tissues - A subset of plasma cells are prominent producers of CD95L. AM J PATHOL. 154:193-201.
  • Li-Weber M; Laur O; Hekele A; Coy J; Walczak H; Krammer PH. (Aug 1998). A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation. Eur J Immunol. 28:2373-2383. DOI.
  • De Laurenzi V; Hahne M; Walczak H; Medema JP. (21 May 1998). We aim to refresh science, not to rebel. NATURE. 393:206-206.
  • Degli-Esposti MA; Smolak PJ; Walczak H; Waugh J; Huang CP; DuBose RF; Goodwin RG; Smith CA. (6 Oct 1997). Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 186:1165-1170.
  • Walczak H; DegliEsposti MA; Johnson RS; Smolak PJ; Waugh JY; Boiani N; Timour MS; Gerhart MJ; et alSchooley KA; Smith CA; Goodwin RG; Rauch CT. (1 Sep 1997). TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386-5397.
  • Sträter J; Wellisch I; Riedl S; Walczak H; Koretz K; Tandara A; Krammer PH; Möller P. (Jul 1997). CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology. 1:345-348.
  • Chlichlia K; Busslinger M; Peter ME; Walczak H; Krammer PH; Schirrmacher V; Khazaie K. (15 May 1997). ICE-proteases mediate HTLV-I tax-induced apoptotic T-cell death. ONCOGENE. 14:2265-2272.
  • Muller M; Strand S; Hug H; Heinemann EM; Walczak H; Hofmann WJ; Stremmel W; Krammer PH; et alGalle PR. (1 Feb 1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J CLIN INVEST. 99:403-413.
  • Sträter J; Walczak H; Krammer PH; Möller P. (Dec 1996). Simultaneous in situ detection of mRNA and apoptotic cells by combined hybridization and TUNEL. J Histochem Cytochem. 44:1497-1499.
  • Herr I; Balemans L; Bohler T; Walczak H; Debatin KM. (Jul 1996). Monitoring of CD95 (APO-1/Fas) ligand expression in human T cells by quantitative RT-PCR. CELL DEATH DIFFER. 3:299-305.
  • Moller P; Walczak H; Riedl S; Strater J; Krammer PH. (Jul 1996). Paneth cells express high levels of CD95 ligand transcripts - A unique property among gastrointestinal epithelia. AM J PATHOL. 149:9-13.
  • Walczak H; Dhein J; Peter ME; Krammer PH. (Apr 1996). Activation-induced T cell death. CELL DEATH DIFFER. 3:245-245.
  • Sträter J; Walczak H; Wellisch I; Riedl S; Koretz K; Krammer PH; Möller P. (1996). [Normal colon epithelium is highly sensitive to CD95-induced apoptosis. Indication for a role of cell death-induced CD95/CL95L systems under inflammatory inflammatory conditions?]. Verh Dtsch Ges Pathol. 80:217.
  • PETER ME; DHEIN J; EHRET A; HELLBARDT S; WALCZAK H; MOLDENHAUER G; KRAMMER PH. (Nov 1995). APO-1 (CD95)-DEPENDENT AND (CD95)-INDEPENDENT ANTIGEN RECEPTOR-INDUCED APOPTOSIS IN HUMAN T-CELL AND B-CELL LINES. INT IMMUNOL. 7:1873-1877.
  • GALLE PR; HOFMANN WJ; WALCZAK H; SCHALLER H; OTTO G; STREMMEL W; KRAMMER PH; RUNKELL L. (1 Nov 1995). INVOLVEMENT OF THE CD95 (APO-1/FAS) RECEPTOR AND LIGAND IN LIVER-DAMAGE. J EXP MED. 182:1223-1230.
  • PETER ME; HELLBARDT S; SCHWARTZALBIEZ R; WESTENDORP MO; WALCZAK H; MOLDENHAUER G; GRELL M; KRAMMER PH. (Jul 1995). CELL-SURFACE SIALYLATION PLAYS A ROLE IN MODULATING SENSITIVITY TOWARDS APO-1-MEDIATED APOPTOTIC CELL-DEATH. CELL DEATH DIFFER. 2:163-171.
  • WESTENDORP MO; FRANK R; OCHSENBAUER C; STRICKER K; DHEIN J; WALCZAK H; DEBATIN KM; KRAMMER PH. (8 Jun 1995). SENSITIZATION OF T-CELLS TO CD95-MEDIATED APOPTOSIS BY HIV-1 TAT AND GP120. NATURE. 375:497-500.
  • Dhein J; Walczak H; Westendorp MO; Bäumler C; Stricker K; Frank R; Debatin KM; Krammer PH. (Jun 1995). Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Behring Inst Mitt. 13-20.
  • DHEIN J; WALCZAK H; BAUMLER C; DEBATIN KM; KRAMMER PH. (2 Feb 1995). AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95). NATURE. 373:438-441.
  • Krammer PH; Dhein J; Walczak H; Behrmann I; Mariani S; Matiba B; Fath M; Daniel PT; et alKnipping E; Westendorp MO. (Dec 1994). The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 142:175-191.
  • BEHRMANN I; WALCZAK H; KRAMMER PH. (Dec 1994). STRUCTURE OF THE HUMAN APO-1 GENE. EUR J IMMUNOL. 24:3057-3062.
  • SCHULZEOSTHOFF K; WALCZAK H; DROGE W; KRAMMER PH. (Oct 1994). CELL-NUCLEUS AND DNA FRAGMENTATION ARE NOT REQUIRED FOR APOPTOSIS. J CELL BIOL. 127:15-20.
  • Dhein J; Behrmann I; Daniel PT; Debatin KM; Klas C; Möller P; Oehm A; Trauth BC; et alWalczak H; Krammer PH. (Aug 1994). APO-I-mediated apoptosis in normal and malignant lymphocytes. Biochem Soc Trans. 22:598-600.
  • LICHTER P; WALCZAK H; WEITZ S; BEHRMANN I; KRAMMER PH. (Sep 1992). THE HUMAN APO-1 (APT) ANTIGEN MAPS TO 10Q23, A REGION THAT IS SYNTENIC WITH MOUSE CHROMOSOME-19. GENOMICS. 14:179-180.

Conferences

  • Gerlach B; Cordier S; Schmukle AC; Emmerich CH; Rieser E; Haas TL; Webb AI; Rickard JA; et alAnderton H; Wong WWL; Nachbur U; Gangoda L; Warnken U; Purcell AW; Silke J; Walczak H. LINEAR UBIQUITINATION PREVENTS INFLAMMATION AND REGULATES IMMUNE SIGNALLING. 60:11-11. (Jun 2011).
  • Haas TL; Emmerich CH; Gerlach B; Warnken U; Wenger T; Koschny R; Silke J; Walczak H. A NOVEL UBIQUITIN LIGASE RECRUITED TO THE TNF-R1 SIGNALLING COMPLEX IS REQUIRED FOR EFFICIENT TNF-INDUCED NF-kappa B ACTIVATION AND GENE INDUCTION. 691:659-659. (2011).
  • Vogler M; Walczak H; Stadel D; Genze F; Moller P; Simmet T; Debatin KM; Fulda S. A novel paradigm for apoptosis-based therapy of pancreatic cancer: sensitizer/inducer concept of XIAP inhibitors combined with TRAIL. 6:85-85. (Oct 2008).
  • Geserick P; Hupe M; Gollnick H; Walczak H; Leverkus M. The Inhibitor-of-apoptosis (IAP) protein family member XIAP is an important downstream regulator of death receptor-mediated apoptosis. 17:275-275. (Mar 2008).
  • Diessenbacher P; Hupe M; Sprick MR; Kerstan A; Geserick P; Haas TL; Wachter T; Neumann M; et alWalczak H; Silke J; Leverkus M. NF-kappa B inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. 16:271-271. (Mar 2007).
  • Geserick P; Drewniok C; Diessenbacher P; Kavuri S; Sprick MR; Haas TL; Gollnick H; Walczak H; et alLeverkus M. cFLIP regulates death receptor sensitivity to TRAIL- or CD95L-mediated apoptosis in human melanoma cells. 16:251-252. (Mar 2007).
  • Verheij M; Wissink E; Verbrugge I; Vink S; Schader M; Schaefer U; Walczak H; Borst J. Trail enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. 81:S31-S32. (Oct 2006).
  • Wissink EHJ; Verbrugge I; Vink SR; Schader MB; Schaefer U; Walczak H; Borst J; Verheij M. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. 80:214-222. (Aug 2006). DOI.
  • Ganten T; Koschny R; Sykora J; Schulze-Bergkamen H; Buechler P; Haas TL; Schader M; Untergasser A; et alStremmel W; Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of trail either alone or in combination with chemotherapeutic drugs. 130:A750-A750. (Apr 2006).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook